Admin

Mike Pomianek's article titled “Could Secret Sales Bar Your Ability to Patent a Medical Device?” was published Medical Device and Diagnostic Industry (MD+DI). Read more.

Just because your issued patent was examined by the USPTO does not mean that it is free from challenge. Your competitors may, of course, scrutinize your patent and use IPR to challenge its validity—po...

You found a great prior art reference for your IPR petition. But if that reference isn’t a patent or patent application, you’ll need to think carefully about how to prove that the reference was actual...

Oona Johnstone and Andrew William's article, titled "Biopharma IPR Trends - 2019 Mid-Year Update," appeared in the April issue of Life Science Leader. Read more.

In September 2018, the Patent Office created the Precedential Opinion Panel (or “POP”) to increase transparency and predictability of proceedings before the PTAB by establishing precedent that would g...

(as published by Westlaw IP Journal) In Travel Sentry Inc. v. Tropp, 877 F.3d 1370 (Fed. Cir. 2017), the U.S. Court of Appeals for the Federal Circuit shed some light on how to apply the divided infri...

(as published by DesignNews) When considering intellectual property protection, businesses often overlook the value of design patents and trade dress rights. Products may have ornamentation and/or vis...

This past year, the Supreme Court in SAS Institute v. Iancu held that once the PTAB institutes an IPR trial its subsequent final written decision must address all claims challenged in the petition. Th...

(as published by business.com) In most situations, a patent is the only way to deter a competitor from taking and using a company’s innovations. However, there are many aspects of patent law that are ...

(as published by Law360) On Dec. 4, 2018, the U.S. Supreme Court heard oral arguments in Helsinn Healthcare v. Teva Pharmaceuticals. The question before the court was whether the America Invents Act o...

(as published by Thomson Reuters Westlaw Journal IP) The U.S. Court of Appeals for the Federal Circuit held in a recent en banc decision that the one-year time limit that an accused infringer has to r...

(as published by IPWatchdog)